Market Mover: Vor (VOR) Up at Midday June 22

Equities Staff  |

Vor Biopharma Inc (NASDAQ: VOR) has climbed $0.89 (19.65%) and is currently sitting at $5.44, as of 12:11:38 est on June 22.

77,195 shares exchanged hands.

The Company has risen 6.34% over the last 5 days and shares have risen 0.89% over the last 30 days.

Vor anticipates its next earnings on 2022-08-08.

For technical charts, analysis, and more on Vor visit the company profile.

About Vor Biopharma Inc

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

To get more information on Vor Biopharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Vor Biopharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content